RevImmune
PrivateLast Round
Grant
Mar 30, 2021
Momentum Score
25 /100
Company Overview
RevImmune is a biotechnology company developing CYT107, a T-cell growth factor, as an immune therapy for infectious diseases and cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
RevImmune Comps
Public and private peers based on sector, stage, and business model.
RevImmune Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Mar 30, 2021 |
RevImmune Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Cancer Research Institute | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 19, 2026
Monthly visitors increased 118% MoM.
- Apr 25, 2026
Monthly visitors increased 334% MoM, from 94 to 408.
RevImmune Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about RevImmune's valuation, stock price, and market status.
